News – Page 482 – Endpoints News

Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?

3 years ago

You can add a colorful Australian mining tycoon to the list of billionaires betting on biotech

3 years ago

David Baker lab spinout scores seed funding to build a biosensor from engineered protein

3 years ago

Enhertu strikes again with a PhIII success in another breast cancer population

3 years ago

Carlyle finds its first big biotech bet after teaming with Abingworth

3 years ago

Sometimes you win. Sometimes you lose. And sometimes it's just another PhIII canakinumab fail

3 years ago

Historic drug pricing reforms pass; Pfizer acquires GBT; The long search for non-opioid pain drugs; and more

3 years ago

House passes historic drug pricing reforms, lining up decades-in-the-making win for Biden and Democrats

3 years ago

Do pharma TV and social ads work? Pharma marketing agencies adopting new tech solutions to find out

3 years ago

Pear Therapeutics touts Q2 growth while scaling back full-year goals and chopping 9% of staff

3 years ago

Senate Finance chair continues his investigation into pharma taxes with requests for Amgen

3 years ago

Paving the way for Merck's buyout, Seagen loses arbitration dispute with Daiichi Sankyo over ADC tech

3 years ago

Abbott pumps $450M+ into new Ireland-based manufacturing site project and hiring spree

3 years ago

FDA approves second indication for AstraZeneca and Daiichi's Enhertu in less than a week

3 years ago

J&J to remove talc products from shelves worldwide, replacing with cornstarch-based portfolio

3 years ago

CSL brings Seqirus, Vifor under parent umbrella brand in identity revamp

3 years ago

Checkpoint ends trial due to Russian invasion; Terns lines up more cash for NASH

3 years ago

‘The placebo caught up’: Months after diabetic nerve pain fail, Aptinyx sees another pain trial fall through

3 years ago

Bolt throws a wrench in the pipeline, looking to conserve cash

3 years ago

Unity finds itself with a finite amount of cash as new data provide a ray of hope for investors

3 years ago

Larimar to respond to FDA this quarter on 15-month clinical hold of PhI Friedreich's ataxia drug

3 years ago

Gold for adults, silver for infants: Pfizer's Prevnar 2.0 headed to FDA months after Merck's green light

3 years ago

Cerevel's Tony Coles is still counting his money as a rival's boost helps fuel a potential $609M windfall

3 years ago

CEO of Doudna spinout: Within five years, genome editors will have a 'really big impact' on patients' lives

3 years ago

First page Previous page 479 480 481482483 484 485 Next page Last page